Close Menu

NEW YORK – An assay from Roche to test immunocompromised transplant recipients for adenovirus infections has been CE marked, the company announced on Wednesday. The test adds a fourth component to the firm's transplant monitoring virology menu and is now commercially available in countries accepting the CE mark.

The PCR-based adenovirus test provides detection and quantification of adenovirus, with calibration traceable to the World Health Organization international standard for adenovirus and reports in International Units per milliliter (IU/mL), the firm said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.